Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.

Abstract

The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P < or = .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P < or = .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P < or = .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.

• Authors: Peter J Kahrilas, Philip Miner, John Johanson, Lian Mao, Leonard Jokubaitis, Sheldon Sloan
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 50 Issue 11 Pg. 2009-18 (Nov 2005) ISSN: 0163-2116 [Print] United States
• PMID: 16240208 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Antacids
• Benzimidazoles
• Enzyme Inhibitors
• Rabeprazole
• Omeprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Adult
• Antacids (therapeutic use)
• Benzimidazoles (adverse effects, therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Enzyme Inhibitors (adverse effects, therapeutic use)
• Female
• Gastroesophageal Reflux (drug therapy)
• Humans
• Male
• Omeprazole (adverse effects, analogs & derivatives, therapeutic use)
• Rabeprazole